Market Overview

Sterne Agee Sees 16% Upside for Actavis, Initiates Coverage


Shares of Actavis (NYSE: ACT) are up 2.3 percent to $198.42 in Wednesday's trading after Sterne Agee initiated coverage on the stock with a Buy rating and $230 price target.

Analyst Shibani Malhotra sees upside “to the company's pro-revenue and synergy targets, and expects management to continue to implement on its disciplined inorganic growth strategy.”

The analyst is also bullish on the company's growth profile following its recent merger with Forest Laboratories.

Latest Ratings for ACT

Jun 2015Initiates Coverage onOutperform
May 2015MaintainsBuy
May 2015MaintainsPositive

View More Analyst Ratings for ACT
View the Latest Analyst Ratings

Posted-In: forest laboratories Shibani Malhotra Sterne AgeeAnalyst Color Initiation Analyst Ratings


Related Articles (ACT)

View Comments and Join the Discussion!

Latest Ratings

WSCInitiates Coverage On19.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Pepsi Earnings Preview: Analysts Favor A Refreshing Quarter

Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing